

**Beyond ADCs: Exploring Novel Therapeutic Opportunities in  
Platinum Resistant Ovarian Cancer  
June 20, 2025  
Colorado Springs, CO**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An **"ineligible company"** is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<b>Planning Disclosures</b>				
Katherine Fuh, MD, PhD	<b>Planner/ Moderator</b>		Aravive; AstraZeneca; GlaxoSmithKline; Immunogen; Share 3% of the 33% of the investigators	Consultant (Aravive; AstraZeneca; GlaxoSmithKline; Immunogen) Intellectual Property -Patent(Share 3% of the 33% of the investigators))
<b>Speaker Disclosures</b>				
Dana Chase, MD	<b>Speaker</b>		AstraZeneca; ImmunoGen; GSK; Clovis	Consultant
Katherine Fuh, MD, PhD	<b>Speaker</b>		Aravive; AstraZeneca; GlaxoSmithKline; Immunogen; Share 3% of the 33% of the investigators	Consultant (Aravive; AstraZeneca; GlaxoSmithKline; Immunogen) Intellectual Property-Patent (Share 3% of the 33% of the investigators)
Debra Richardson, MD	<b>Speaker</b>		AstraZeneca; Mersana; GlaxoSmithKline; Immunogen; Eisai; Daiichi Sankyo	Consultant (Mersana) Advisor (AstraZeneca; GlaxoSmithKline; Immunogen; Eisai; Daiichi Sankyo) Speaker (GlaxoSmithKline) Research Grant (GlaxoSmithKline)
Holley Engbert	<b>Staff</b>	<b>X</b>		
Heather Rush	<b>Staff</b>	<b>X</b>		
Michelle N Small, MPH	<b>Reviewer/Staff</b>	<b>X</b>		
Angeles Alvarez-Secord, MD	<b>Reviewer/Edu-Chair</b>		AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Blo	Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL

## FACULTY DISCLOSURE INFORMATION

				Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL ) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio)
--	--	--	--	--